BJH - volume 11, issue Abstract Book BHS, february 2020
W. Vandemoortele , G. Vanbutsele , M. Valcke , T. Kerre MD, PhD
BJH - volume 11, issue Abstract Book BHS, february 2020
S. Servais MD, PhD, F. Baron MD, PhD, C. Lechanteur PhD, E. Baudoux MD, A. Briquet PhD, D. Selleslag MD, J. Maertens MD, PhD, X. Poiré MD, W. Schroyens MD, PhD, C. Graux MD, PhD, A. De Becker MD, R. Schots MD, PhD, P. Zachée MD, PhD, A. Ory , J. Herman , T. Kerre MD, PhD, Y. Beguin MD, PhD
BJH - volume 11, issue Abstract Book BHS, february 2020
S. Bonte , S. Van Gassen , A. Couckuyt , V. Janda , I. Moors MD, A. Delie , S. Kennes , J. Philippé MD, PhD, Y. Saeys , T. Kerre MD, PhD
BJH - volume 10, issue 8, december 2019
T. Feys MBA, MSc, G. Roex , Y. Beguin MD, PhD, T. Kerre MD, PhD, X. Poiré MD, P. Lewalle MD, PhD, P. Vandenberghe MD, PhD, D. Bron MD, PhD, S. Anguille MD, PhD
Chimeric antigen receptor (CAR) T-cell therapy is a new cancer immunotherapy targeting specific cell surface antigens. This type of adoptive cell immunotherapy has been a breakthrough in the treatment of aggressive B-cell lymphoma and B-cell precursor acute lymphoblastic leukaemia (ALL) and is currently also being studied in other cancer types, including multiple myeloma and chronic lymphocytic leukaemia. This review will discuss the recent clinical developments and future perspectives of CAR T-cell therapy, with a focus on the clinical trials that led to the FDA and EMA approval of tisagenlecleucel (Kymriah®, Novartis) and axicabtagene ciloleucel (Yescarta®, Gilead) for the treatment of childhood/adult relapsed/refractory (r/r) B-cell precursor ALL and aggressive B-cell non-Hodgkin lymphoma.
(BELG J HEMATOL 2019;10(8):301–10)
Read moreBJH - volume 10, issue 2, march 2019
S. Snauwaert MD, PhD, J. Lemmens MD, A. Janssens MD, PhD, T. Kerre MD, PhD
High-dose chemotherapy and autologous or allogeneic haematopoietic stem cell transplantation are widely used in the treatment of lymphoproliferative diseases. For chemo-sensitive relapsed lymphoma (Hodgkin’s and non-Hodgkin’s lymphoma) high-dose chemotherapy and autologous stem cell transplantation are generally accepted as a standard treatment. Emerging data exist for the use of haematopoietic stem cell transplantation in other disease stages for mantle cell lymphoma, follicular lymphoma and some T-cell lymphomas. The use of haematopoietic stem cell transplantation in other conditions is more controversial and remains a clinical option for selected patients or experimental within the framework of a clinical trial.
(BELG J HEMATOL 2019;10(2):69–79)
Read moreBJH - volume 10, issue Abstract Book BHS, february 2019
A. De Becker MD, R. Schots MD, PhD, T. Kerre MD, PhD, D. Mazure , J. Maertens MD, PhD, E. Baudoux , C. Lechanteur , Y. Beguin MD, PhD
BJH - volume 9, issue 7, december 2018
A. Delie , T. Kerre MD, PhD, I. Moors MD
Since several years, it has become clear that intermediate-risk acute myeloid leukaemia patients in an acceptable clinical condition can benefit from allogeneic stem cell transplantation thanks to the improvement in relapse free survival. This study retrospectively analysed the outcome of all intermediate-risk acute myeloid leukaemia patients treated with intensive chemotherapy at the Ghent University Hospital between 01-01-2013 and 30-04-2017 in an effort to determine the impact of a new in-hospital treatment guideline adopted in April 2015. This guideline recommends all intermediate-risk acute myeloid leukaemia patients who are fit for intensive therapy to proceed to allogeneic stem cell transplantation in first complete remission. Unfortunately, we could not demonstrate an improvement in the relapse free survival after implementation of the treatment guideline. Nevertheless, exploratory analysis of the entire group suggests a survival benefit from allogeneic stem cell transplantation, with significantly improved relapse free survival and a trend towards a better overall survival.
(BELG J HEMATOL 2018;9(7):285–9)
Read more
Top
